Core Insights - Amplify Seymour Cannabis ETF (NYSEARCA:CNBS) achieved a 17% gain in 2025, indicating a positive performance in the cannabis sector [1] Group 1 - The 17% gain in 2025 may not fully reflect the underlying challenges faced by the cannabis industry [1] - The ETF's performance is influenced by various market dynamics and regulatory changes affecting cannabis companies [1] - Investors should consider the broader context of the cannabis market when evaluating the ETF's performance [1]

ATLANTA, Dec. 19, 2025 /PRNewswire/ -- UC Asset Limited Partnership (OTCQB: UCASU) today issued a statement applauding President' Trump's decision to rescheduling marijuana from Schedule I to Schedule III, which is a significant measure of deregulation for cannabis industry. UC Asset, which stands for Ultimate Cannabis Asset, is one of the only four US public companies devoted to investing in cannabis properties. Its management claims to have built the "best performing" cannabis property portfolio among US ...

Core Viewpoint - The Amplify Seymour Cannabis ETF (CNBS) has experienced significant growth, reaching a 52-week high and increasing by 199.07% from its 52-week low price of $13.96/share, indicating strong momentum in the cannabis sector [1][2]. Group 1: Fund Performance - CNBS employs an active strategy to provide diversified exposure across the U.S. cannabis ecosystem, charging 76 basis points in annual fees [1]. - The fund has a positive weighted alpha of 19.45, suggesting potential for further gains in the near term [3]. Group 2: Market Drivers - The cannabis sector is gaining renewed attention due to President Trump's plan to ease federal regulations on marijuana, which could serve as a significant policy tailwind [2]. - Reclassifying marijuana to a lower-risk category could enhance research funding and improve access to capital by reducing legal constraints [2].

Group 1 - The Hecht Commodity Report is a comprehensive source for commodities analysis, covering market movements of over 29 different commodities and providing various trading recommendations [1][2] - The AdvisorShares Pure Cannabis ETF (YOLO) is highlighted as one of the most liquid cannabis ETFs, trading at $2.93 per share with nearly $38 million in assets under management as of December 2 [2] Group 2 - The report includes bullish, bearish, and neutral calls, along with actionable ideas for traders and investors [1][2]

The Hecht Commodity Report is one of the most comprehensive commodities reports available today from a top-ranked author in commodities, forex, and precious metals. My weekly report covers the market movements of over 29 different commodities and provides bullish, bearish, and neutral calls, directional trading recommendations, and actionable ideas for traders and investors.One of the most liquid cannabis ETFs is the AdvisorShares Pure Cannabis ETF ( YOLO ). At $2.93 per share on December 2, YOLO had nearly ...

Core Viewpoint - Cannabis stocks have experienced significant growth recently, driven by favorable developments in Washington, including President Trump's endorsement of CBD for seniors and discussions about reclassifying marijuana as a schedule 3 drug [1][4]. Industry Overview - Cannabis stocks have doubled in value over the past three months amid hopes for federal reform, although past experiences have made investors cautious about the sustainability of this growth [2][6]. - The cannabis industry has faced challenges over the last five years, particularly due to unfulfilled promises of reform from politicians [3][6]. Regulatory Environment - Currently classified as a schedule one drug, there are discussions about rescheduling cannabis to schedule three, which would involve coordination between the Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA) [4][5]. - An executive order from President Trump could initiate this rescheduling process, but congressional support and involvement from the Department of Justice (DOJ) would still be necessary [5]. Investment Landscape - There is a notable disconnect in the U.S. cannabis investment landscape, where Canadian companies can list on major U.S. exchanges despite restrictions on THC cannabis operations in the U.S. [7][8]. - U.S. multi-state operators, which conduct significant business in states with medical cannabis dispensaries, face challenges due to federal law, including limitations on banking and exchange listings [9][10]. Market Dynamics - The largest cannabis fund in the world focuses on U.S. multi-state operators and is listed on the New York Stock Exchange, providing investors with access to these companies [10]. - Rescheduling cannabis could trigger a domino effect, allowing these companies to access banking services and institutional investments, potentially reversing losses from the past five years [11]. Company Highlights - Top investment picks include Cural Leaf, True Leave, Cresco Labs, and Verono, which are positioned well for potential reform and operate in multiple states [12][13].